Abstract
OBJECTIVE
Dehydroepiandrosterone (DHEA) and Dehydroepiandrosterone-sulfate (DHEA-S) are the most abundant steroid hormones in the body. Recently, DHEA-S has gained interest as an antidepressant substance, with positive effects on autoimmune disease such as lupus and ulcerative colitis, as well as obesity, cancer, cardiovascular disease and diabetes. Its effect on insulin resistance is also assumed to be positive, but has not as yet been confirmed. The present cross-over clinical trial was conducted to evaluate the efficacy of DHEA and placebo on insulin resistance.
DESIGN
Participants were selected among relatives of diabetic patients who were referred to the Isfahan Endocrine Research Center because of Impaired Glucose Tolerance (IGT) test. Thirty IGT patients were treated randomly with DHEA (50 mg/day) or placebo by cross-over clinical trial for six months and insulin resistance between the beginning and the end of each three months treatment period was assessed.
RESULTS
At the end of the first three months, the mean changes from baseline of the various parameters in the drug group were: DHEA-S, 2.5 µmol/l (p=0.008); Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), 0.6 (p=0.6); insulin, 7.1 pmol/l (p=0.3) and FPG, 0.5mmol/l (p=0.1). The changes in the placebo group were: DHEA-S, 0.08 µmol/l (p=0.6); HOMA-IR, 0.9 (p=0.03); FPG, 0.8 mmol/l (p=0.1); insulin, 25.1 pmol/l (p=0.05). In the second three months, the mean changes in the drug group were: DHEA-S, 4.5 µmol/l (p=0.003); Fasting Plasma Glucose (FPG), 0.1 mmol/l (p = 0.4); insulin, 4.3 pmol/l (p=0.2); HOMA-IR, 0.3 (p=0.1) and the changes in placebo group were: DHEA-S, 0.7 µmol/l (p=0.5); FPG, 0.3 mmol/l (p=0.3); insulin, 10.7 pmol/l (p=0.1); HOMA-IR, 0.6 (p=0.03).
CONCLUSION
DHEA did not reduce insulin resistance, although there was a tendency to improvement. The data indicate a possible but not clearly favorable effect of DHEA on insulin resistance.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Baulieu EE, 1996 Dehydroepiandrosterone (DHEA-S): A Fountain of youth? J Clin Endocrinol Metab 81: 3147–3151.
Dhatariya K, Bigelow ML, Nair KS, 2005 Effect of Dehydroepiandrosterone Replacement on Insulin Sensitivity and Lipids in Hypoadrenal Women. Diabetes 54: 765–769.
Nair KS, Rizza RA, Brien P, et al, 2006 DHEA-S in elderly women and DHEA-S or testosterone in elderly men. N Engl J Med 355: 1647–1659.
Arlt W, 2006 Dehydroepiandrosterone replacement therapy. Current Opinion in Endocrinology & Diabetes 13: 291–305.
Lasco A, Frisina N, Morabito N, et al, 2001 Metabolic effects of DHEA-S therapy in post menopausal women. Eur J Endocirol 145: 457–461.
Nestler JE, Beer NA, Jacobowicz DJ, Colombo C, Beer RM, 1996 Effects of Insulin Reduction with Benfluorex on Serum DHEA-S and Blood Pressure in Hypertensive Middle-Aged and Elderly Men. J Clin Endocrinol Metab 80: 700–706.
Medina MC, Souza LC, Caperuto LC, et al, 2006 Dehydroepiandrosterone increases beta-cell mass and improves the glucose-induced insulin secretion by pancreatic islets from aged rats. FEBS Lett 580: 285–290.
Formoso G, Chen H, Kim J, Montagnani M, Consoli A, Quon M, 2006 Dehydroepiandrosterone Mimics Acute Actions of Insulin to Stimulate Production of Both Nitric Oxide and Endothelin 1 via Distinct Phosphati-dylinositol3-Kinase- and Mitogen-Activated Protein Kinase- Dependent Pathways in Vascular Endothelium. J Molecular Endocrinology 20: 1153–1163.
Dillon J, Yaney G, Zhou Y, et al, 2000 Dehydroepiandrosterone Sulfate and B-Cell Function Enhanced Glucose-Induced Insulin Secretion and Altered Gene Expression in Rodent Pancreatic B-Cells. J Diabetes 49: 2012–2020.
Kimura M, Tanaka SI, Yamada Y, Kiuchi Y, Yamakawa T, Sekihara H, 1998 Dehydroepiandrosterone decreases serum tumor necrosis factor and restores insulin sensitivity. J Endocrinology 139: 3249–3253.
Saruç M, Yüceyar H, Ayhan S, Türkel N, Tuzcuoglu I, Can M, 2003 The association of dehydroepiandrosterone, obesity, waist-hip ratio and insulin resistance with fatty liver in postmenopausal women, a hyperinsulinemic euglycemic insulin clamp study. Hepatogastroenterology 50: 771.
Mino D, Amato D, Cuevas ML, et al, 2002 A relationship of insulin resistance and overweight with cortisol and dehydroepiandrosterone-sulfate levels. Arch Med Res 33: 524–530.
Liu HK, Green BD, McClenaghan NH, McCluskey JT, Flatt PR, 2006 Deleterious effects of supplementation with dehydroepiandrosterone sulphate or dexamethasone on rat insulin-secreting cells under in vitro culture condition. Biosci Rep 26: 31–38.
Couch RM, 1992 Dissociation of cortisol and adrenal androgen secretion in poorly controlled insulin-dependent diabetes mellitus. Acta Endocrinologica 127: 115–117.
Fukui M, Kitagawa Y, Nakamura N, et al, 2005 Serum dehydroepiandrosterone sulfate concentration and carotid atherosclerosis in men with type 2 diabetes. Atherosclerosis 181: 339–344.
Kawano H, Yasue H, Kitagawa A, et al, 2003 Dehydroepiandrosterone Supplementation Improves Endothelial Function and Insulin Sensitivity in Men. J Clin Endocrinol Metab 88: 3190–3195.
Kameda W, Daimon M, Oizumi T, et al, 2005 Association of decrease in serum dehydroepiandrosterone sulfate levels with the progression to type 2 diabetes in men of a Japanese population: the Funagata Study. J Metab 54: 669–676.
Fukui M, Kitagawa Y, Nakamura N, Kadono M, Hasegawa G, Yoshikawa T, 2004 Association between urinary albumin excretion and serum dehydroepiandrosterone sulfate concentration in male patients with type 2 diabetes: a possible link between urinary albumin excretion and cardiovascular disease. Diabetes Care 2712: 2893–2897.
Yamada Y, Sekihara H, Omura M, et al, 2007 Changes in serum sex hormone profiles after short term low dose administration of DHEA-S to young and elderly persons. J Endocrine 54: 153–162.
Basu R, Dalla Man C, Campioni M, et al, 2007 Two years of treatment with dehydroepiandrosterone does not improve insulin secretion, insulin action, or postprandial glucose turnover in elderly men or women. Diabetes: 753–766.
Yamauchi A, Takei I, Kasuga A, et al, 1996 Depression of dehydroepiandrosterone in Japanese diabetic men comparison between non-insulin-dependent diabetes mellitus and impaired glucose tolerance. Eur J Endocrinol 135: 101–104.
Jedrzejuk D, Medras M, Milewicz A, Demissie M, 2003 Dehydroepiandrosterone replacement in healthy men with age-related decline of DHEA-S-S: effects on fat distribution, insulin sensitivity and lipid metabolism. J Aging Male 6: 151–156.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Talaei, A., Amini, M., Siavash, M. et al. The effect of Dehydroepiandrosterone on insulin resistance in patients with impaired glucose tolerance. Hormones 9, 326–331 (2010). https://doi.org/10.14310/horm.2002.1284
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.14310/horm.2002.1284